TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      National Oncology Trainee Collaborative for Healthcare Research
    • Source:
      Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
    • Subject Terms:
      Uterine Neoplasms*/therapy ; Uterine Neoplasms*/mortality ; Uterine Neoplasms*/pathology ; Sarcoma*/therapy ; Sarcoma*/mortality ; Leiomyosarcoma*/therapy ; Leiomyosarcoma*/pathology ; Leiomyosarcoma*/mortality; Humans ; Female ; Retrospective Studies ; Middle Aged ; United Kingdom ; Aged ; Adult ; Treatment Outcome ; Neoplasm Staging ; Chemotherapy, Adjuvant
    • Abstract:
      Background: Although rare, uterine sarcomas account for a high proportion of uterine cancer mortality. Treatment options and robust trial data are limited.
      Objectives: The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) is a UK-wide study by the National Oncology Trainees Collaborative for Healthcare Research which aimed to characterise this patient cohort.
      Design: A retrospective descriptive cohort study. Patients with carcinosarcomas/mixed Mullerian tumours, non-uterine gynaecological sarcomas and uterine metastases were excluded. Routine clinical data, including general patient demographics, diagnosis, treatment and outcomes, were collated and pseudonymised.
      Setting: Patients diagnosed with uterine sarcoma in the UK National Health Service between 1 January 2008 and 31 December 2017 were identified from electronic records.
      Participants: A total of 406 patients from eight centres were eligible for inclusion.
      Results: The median age at diagnosis was 56 years, with leiomyosarcoma the most common diagnosis (54.4%). The majority (57.9%) were diagnosed at the International Federation of Gynecology and Obstetrics stage I, with 19.7% diagnosed at stage IV. Nearly half (45.2%) of the patients received at least one line of chemotherapy, of which most (81.0%) received doxorubicin first-line. In the stage I group 7.4% received adjuvant chemotherapy and 15.0% received adjuvant radiotherapy. Median overall survival was 37 months; however, survival varied significantly by stage at diagnosis (stage I: 105 months; stage II: 33 months; stage III: 19 months; stage IV: 14 months).
      Conclusions: Our data highlight the diversity in patient management in uterine sarcoma and a marked survival advantage for patients diagnosed with stage I disease. These data highlight the importance of a multidisciplinary approach and describe real-world trends in systemic therapies, radiotherapy and surgical treatment in this rare cancer type.
      Competing Interests: Competing interests: MAB: consultancy: Servier. Honoraria: Servier, Ipsen, AZ, BMS, MSD. Travel: AZ, Ipsen, Servier. ALS: consultancy: AZ, Eisai, MSD, GSK. Speaker fees: Eisai, MSD, GSK. Travel: MSD. The other authors did not declare any conflicts of interest.
      (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.)
    • References:
      Gynecol Oncol. 2016 Jul;142(1):95-101. (PMID: 27208537)
      Histopathology. 2009 Feb;54(3):355-64. (PMID: 19236512)
      Clin Sarcoma Res. 2015 Mar 15;5:8. (PMID: 25810898)
      Lancet Oncol. 2012 Oct;13(10):1045-54. (PMID: 22954508)
      Lancet Oncol. 2016 May;17(5):671-80. (PMID: 27068860)
      Br J Cancer. 2024 May 11;:. (PMID: 38734790)
      Int J Gynecol Cancer. 2015 Jun;25(5):850-7. (PMID: 25853381)
      Eur J Obstet Gynecol Reprod Biol. 2023 Aug;287:166-170. (PMID: 37348383)
      Gynecol Oncol. 2010 Jan;116(1):131-9. (PMID: 19853898)
      Mol Clin Oncol. 2020 Dec;13(6):81. (PMID: 33093955)
      Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:51-58. (PMID: 30306577)
      Eur J Cancer. 2010 Jan;46(1):72-83. (PMID: 19853437)
      JAMA. 2020 Apr 7;323(13):1266-1276. (PMID: 32259228)
      Gynecol Oncol. 2016 Jul;142(1):89-94. (PMID: 27012429)
      Pathology. 2007 Feb;39(1):55-71. (PMID: 17365823)
      Int J Gynecol Cancer. 2016 Jul;26(6):1098-104. (PMID: 27177280)
      Eur J Cancer. 2008 Apr;44(6):808-18. (PMID: 18378136)
      Clin Oncol (R Coll Radiol). 2004 Jun;16(4):261-8. (PMID: 15214650)
      Clin Oncol (R Coll Radiol). 2020 Oct;32(10):632-635. (PMID: 32487502)
      Int J Gynecol Cancer. 2018 Jan;28(1):134-138. (PMID: 29040191)
      Crit Rev Oncol Hematol. 2018 Feb;122:10-20. (PMID: 29458779)
      Crit Rev Oncol Hematol. 2016 Feb;98:302-8. (PMID: 26672915)
      Acta Oncol. 2012 Jul;51(6):694-705. (PMID: 22793037)
      Lancet. 2005 Aug 6-12;366(9484):491-505. (PMID: 16084259)
      Lancet Oncol. 2014 Apr;15(4):415-23. (PMID: 24618336)
    • Grant Information:
      United Kingdom WT_ Wellcome Trust
    • Contributed Indexing:
      Keywords: Adult radiotherapy; CHEMOTHERAPY; Gynaecological oncology; Sarcoma
    • Publication Date:
      Date Created: 20241226 Date Completed: 20241226 Latest Revision: 20250104
    • Publication Date:
      20250104
    • Accession Number:
      PMC11683892
    • Accession Number:
      10.1136/bmjopen-2024-094838
    • Accession Number:
      39725428